The present and future of prostate cancer. The importance of physical activity - a comprehensive review of the literature
DOI:
https://doi.org/10.12775/QS.2024.16.52147Keywords
prostate cancer, prostate cancer diagnosis, prostate cancer treatment, personalized prostate cancer medicine, physical activity and sports in prostate cancer, advanced prostate cancer therapiesAbstract
Introduction: Prostate cancer is one of the most common malignancies affecting men worldwide, which poses a serious health risk due to its high incidence and impact on quality of life. Despite advances in the diagnosis and treatment of this condition, the management of advanced and aggressive forms of the disease remains complex.
Aim of the Study: The aim of this study is to review current diagnostic methods, treatment strategies and prognostic factors in prostate cancer, that a particular focus on personalized medicine and multidisciplinary approaches to improve patient outcomes.
Materials and Methods: A comprehensive literature review was conducted using PubMed sources and other scientific databases, focusing on currently available publications. The literature available in the PubMed database was reviewed using the following keywords: “prostate cancer” “prostate cancer diagnosis”, “prostate cancer treatment”, “personalized medicine for prostate cancer”, “physical activity in prostate cancer”. The review included studies on prostate cancer epidemiology, pathogenesis, advances in diagnosis, treatment, physical activity and future research directions.
Conclusions: Advances in diagnostic technologies and emerging new therapies have significantly improved the prognosis for patients with prostate cancer. However, continued research and commitment to personalized treatment strategies are essential to meet the challenges of advanced disease. Multidisciplinary collaboration and patient-centered care remain key to optimizing outcomes and improving quality of life for prostate cancer patients.
References
R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2020.,” CA. Cancer J. Clin., vol. 70, no. 1, pp. 7–30, Jan. 2020, doi: 10.3322/caac.21590.
P. Rawla, “Epidemiology of Prostate Cancer.,” World J. Oncol., vol. 10, no. 2, pp. 63–89, Apr. 2019, doi: 10.14740/wjon1191.
M. S. Litwin and H.-J. Tan, “The Diagnosis and Treatment of Prostate Cancer: A Review.,” JAMA, vol. 317, no. 24, pp. 2532–2542, Jun. 2017, doi: 10.1001/jama.2017.7248.
H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.,” CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
M. B. Culp, I. Soerjomataram, J. A. Efstathiou, F. Bray, and A. Jemal, “Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.,” Eur. Urol., vol. 77, no. 1, pp. 38–52, Jan. 2020, doi: 10.1016/j.eururo.2019.08.005.
F. H. Schröder et al., “Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.,” Lancet (London, England), vol. 384, no. 9959, pp. 2027–2035, Dec. 2014, doi: 10.1016/S0140-6736(14)60525-0.
A. Heidenreich et al., “EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.,” Eur. Urol., vol. 59, no. 1, pp. 61–71, Jan. 2011, doi: 10.1016/j.eururo.2010.10.039.
E. Castro and R. Eeles, “The role of BRCA1 and BRCA2 in prostate cancer.,” Asian J. Androl., vol. 14, no. 3, pp. 409–414, May 2012, doi: 10.1038/aja.2011.150.
C. E. DeSantis et al., “Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities.,” CA. Cancer J. Clin., vol. 66, no. 4, pp. 290–308, Jul. 2016, doi: 10.3322/caac.21340.
T. R. Rebbeck, “Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.,” Semin. Radiat. Oncol., vol. 27, no. 1, pp. 3–10, Jan. 2017, doi: 10.1016/j.semradonc.2016.08.002.
S. K. Clinton, E. L. Giovannucci, and S. D. Hursting, “The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions.,” J. Nutr., vol. 150, no. 4, pp. 663–671, Apr. 2020, doi: 10.1093/jn/nxz268.
S. A. Kenfield, M. J. Stampfer, E. Giovannucci, and J. M. Chan, “Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 29, no. 6, pp. 726–732, Feb. 2011, doi: 10.1200/JCO.2010.31.5226.
F. Bray, A. Jemal, N. Grey, J. Ferlay, and D. Forman, “Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.,” Lancet. Oncol., vol. 13, no. 8, pp. 790–801, Aug. 2012, doi: 10.1016/S1470-2045(12)70211-5.
Z. Kote-Jarai et al., “Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.,” Nat. Genet., vol. 43, no. 8, pp. 785–791, Jul. 2011, doi: 10.1038/ng.882.
A. A. Al Olama et al., “A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.,” Nat. Genet., vol. 46, no. 10, pp. 1103–1109, Oct. 2014, doi: 10.1038/ng.3094.
B. J. Feldman and D. Feldman, “The development of androgen-independent prostate cancer,” Nat. Rev. Cancer, vol. 1, no. 1, pp. 34–45, 2001, doi: 10.1038/35094009.
H. I. Scher and C. L. Sawyers, “Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 23, no. 32, pp. 8253–8261, Nov. 2005, doi: 10.1200/JCO.2005.03.4777.
B. S. Taylor et al., “Integrative genomic profiling of human prostate cancer.,” Cancer Cell, vol. 18, no. 1, pp. 11–22, Jul. 2010, doi: 10.1016/j.ccr.2010.05.026.
S. Wang et al., “Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.,” Cancer Cell, vol. 4, no. 3, pp. 209–221, Sep. 2003, doi: 10.1016/s1535-6108(03)00215-0.
T. Ho et al., “Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.,” Eur. Urol., vol. 62, no. 5, pp. 910–916, Nov. 2012, doi: 10.1016/j.eururo.2012.08.015.
K. S. Sfanos and A. M. De Marzo, “Prostate cancer and inflammation: the evidence.,” Histopathology, vol. 60, no. 1, pp. 199–215, Jan. 2012, doi: 10.1111/j.1365-2559.2011.04033.x.
L.-C. Li, P. R. Carroll, and R. Dahiya, “Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment,” JNCI J. Natl. Cancer Inst., vol. 97, no. 2, pp. 103–115, Jan. 2005, doi: 10.1093/jnci/dji010.
W. H. Lee et al., “Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.,” Proc. Natl. Acad. Sci. U. S. A., vol. 91, no. 24, pp. 11733–11737, Nov. 1994, doi: 10.1073/pnas.91.24.11733.
M.-Y. Xu et al., “A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance,” Front. Immunol., vol. 15, 2024, [Online]. Available: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1395047
V. A. Moyer, “Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.,” Ann. Intern. Med., vol. 157, no. 2, pp. 120–134, Jul. 2012, doi: 10.7326/0003-4819-157-2-201207170-00459.
S. Loeb et al., “Overdiagnosis and overtreatment of prostate cancer.,” Eur. Urol., vol. 65, no. 6, pp. 1046–1055, Jun. 2014, doi: 10.1016/j.eururo.2013.12.062.
S. H. Woolf, “Screening for prostate cancer with prostate-specific antigen. An examination of the evidence.,” N. Engl. J. Med., vol. 333, no. 21, pp. 1401–1405, Nov. 1995, doi: 10.1056/NEJM199511233332107.
L. Dickinson et al., “Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.,” Eur. Urol., vol. 59, no. 4, pp. 477–494, Apr. 2011, doi: 10.1016/j.eururo.2010.12.009.
K. K. Hodge, J. E. McNeal, M. K. Terris, and T. A. Stamey, “Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.,” J. Urol., vol. 142, no. 1, pp. 71–75, Jul. 1989, doi: 10.1016/s0022-5347(17)38664-0.
H. Jadvar, “Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.,” Eur. J. Nucl. Med. Mol. Imaging, vol. 40 Suppl 1, no. 0 1, pp. S5-10, Jul. 2013, doi: 10.1007/s00259-013-2361-7.
V. Scattoni et al., “Is extended and saturation biopsy necessary?,” Int. J. Urol. Off. J. Japanese Urol. Assoc., vol. 17, no. 5, pp. 432–447, May 2010, doi: 10.1111/j.1442-2042.2010.02479.x.
H. U. Ahmed et al., “Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.,” Lancet (London, England), vol. 389, no. 10071, pp. 815–822, Feb. 2017, doi: 10.1016/S0140-6736(16)32401-1.
S. Loeb et al., “The prostate health index selectively identifies clinically significant prostate cancer.,” J. Urol., vol. 193, no. 4, pp. 1163–1169, Apr. 2015, doi: 10.1016/j.juro.2014.10.121.
J. Cullen et al., “A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.,” Eur. Urol., vol. 68, no. 1, pp. 123–131, Jul. 2015, doi: 10.1016/j.eururo.2014.11.030.
J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley, and P. A. Humphrey, “The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.,” Am. J. Surg. Pathol., vol. 40, no. 2, pp. 244–252, Feb. 2016, doi: 10.1097/PAS.0000000000000530.
A. V D’Amico et al., “Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.,” JAMA, vol. 280, no. 11, pp. 969–974, Sep. 1998, doi: 10.1001/jama.280.11.969.
J. J. Tosoian, H. B. Carter, A. Lepor, and S. Loeb, “Active surveillance for prostate cancer: current evidence and contemporary state of practice.,” Nat. Rev. Urol., vol. 13, no. 4, pp. 205–215, Apr. 2016, doi: 10.1038/nrurol.2016.45.
L. Klotz, “Active surveillance for prostate cancer: patient selection and management.,” Curr. Oncol., vol. 17 Suppl 2, no. Suppl 2, pp. S11-7, Sep. 2010, doi: 10.3747/co.v17i0.713.
M. R. Cooperberg, P. R. Carroll, and L. Klotz, “Active surveillance for prostate cancer: progress and promise.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 29, no. 27, pp. 3669–3676, Sep. 2011, doi: 10.1200/JCO.2011.34.9738.
G. Novara, V. Ficarra, C. D’Elia, S. Secco, S. Cavalleri, and W. Artibani, “Prospective evaluation with standardised criteria for postoperative complications after robotic-assisted laparoscopic radical prostatectomy.,” Eur. Urol., vol. 57, no. 3, pp. 363–370, Mar. 2010, doi: 10.1016/j.eururo.2009.11.032.
V. Ficarra et al., “Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy.,” Eur. Urol., vol. 62, no. 3, pp. 405–417, Sep. 2012, doi: 10.1016/j.eururo.2012.05.045.
J. A. Eastham et al., “Risk factors for urinary incontinence after radical prostatectomy.,” J. Urol., vol. 156, no. 5, pp. 1707–1713, Nov. 1996.
M. J. Zelefsky et al., “Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.,” Int. J. Radiat. Oncol. Biol. Phys., vol. 70, no. 4, pp. 1124–1129, Mar. 2008, doi: 10.1016/j.ijrobp.2007.11.044.
R. G. Stock, N. N. Stone, J. A. Cesaretti, and B. S. Rosenstein, “Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results.,” Int. J. Radiat. Oncol. Biol. Phys., vol. 64, no. 2, pp. 527–533, Feb. 2006, doi: 10.1016/j.ijrobp.2005.07.981.
W. P. Harris, E. A. Mostaghel, P. S. Nelson, and B. Montgomery, “Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.,” Nat. Clin. Pract. Urol., vol. 6, no. 2, pp. 76–85, Feb. 2009, doi: 10.1038/ncpuro1296.
F. Labrie et al., “New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.,” Clin. Invest. Med., vol. 5, no. 4, pp. 267–275, 1982.
T. W. Flaig and L. M. Glodé, “Management of the side effects of androgen deprivation therapy in men with prostate cancer.,” Expert Opin. Pharmacother., vol. 9, no. 16, pp. 2829–2841, Nov. 2008, doi: 10.1517/14656566.9.16.2829.
L. G. Taylor, S. E. Canfield, and X. L. Du, “Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.,” Cancer, vol. 115, no. 11, pp. 2388–2399, Jun. 2009, doi: 10.1002/cncr.24283.
P. W. Kantoff et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer.,” N. Engl. J. Med., vol. 363, no. 5, pp. 411–422, Jul. 2010, doi: 10.1056/NEJMoa1001294.
E. S. Antonarakis and C. G. Drake, “Current status of immunological therapies for prostate cancer.,” Curr. Opin. Urol., vol. 20, no. 3, pp. 241–246, May 2010, doi: 10.1097/MOU.0b013e3283381793.
J. Mateo et al., “DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.,” N. Engl. J. Med., vol. 373, no. 18, pp. 1697–1708, Oct. 2015, doi: 10.1056/NEJMoa1506859.
M. S. Hofman et al., “[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.,” Lancet. Oncol., vol. 19, no. 6, pp. 825–833, Jun. 2018, doi: 10.1016/S1470-2045(18)30198-0.
M. Bolla et al., “Duration of androgen suppression in the treatment of prostate cancer.,” N. Engl. J. Med., vol. 360, no. 24, pp. 2516–2527, Jun. 2009, doi: 10.1056/NEJMoa0810095.
J. L. Mohler et al., “Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.,” J. Natl. Compr. Canc. Netw., vol. 17, no. 5, pp. 479–505, May 2019, doi: 10.6004/jnccn.2019.0023.
C. M. Friedenreich, Q. Wang, H. K. Neilson, K. A. Kopciuk, S. E. McGregor, and K. S. Courneya, “Physical Activity and Survival After Prostate Cancer.,” Eur. Urol., vol. 70, no. 4, pp. 576–585, Oct. 2016, doi: 10.1016/j.eururo.2015.12.032.
E. Giovannucci and D. Michaud, “The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas,” Gastroenterology, vol. 132, no. 6, pp. 2208–2225, 2007, doi: https://doi.org/10.1053/j.gastro.2007.03.050.
J. A. Rendeiro, C. A. M. P. Rodrigues, L. de Barros Rocha, R. S. B. Rocha, M. L. da Silva, and K. da Costa Cunha, “Physical exercise and quality of life in patients with prostate cancer: systematic review and meta-analysis.,” Support. care cancer Off. J. Multinatl. Assoc. Support. Care Cancer, vol. 29, no. 9, pp. 4911–4919, Sep. 2021, doi: 10.1007/s00520-021-06095-y.
R. U. Newton and D. A. Galvão, “Exercise in prevention and management of cancer.,” Curr. Treat. Options Oncol., vol. 9, no. 2–3, pp. 135–146, Jun. 2008, doi: 10.1007/s11864-008-0065-1.
K. S. Courneya, “Exercise in cancer survivors: an overview of research.,” Med. Sci. Sports Exerc., vol. 35, no. 11, pp. 1846–1852, Nov. 2003, doi: 10.1249/01.MSS.0000093622.41587.B6.
D. A. Galvão and R. U. Newton, “Review of exercise intervention studies in cancer patients.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 23, no. 4, pp. 899–909, Feb. 2005, doi: 10.1200/JCO.2005.06.085.
K. Toohey, M. Hunter, C. Paterson, R. Mortazavi, and B. Singh, “Exercise Adherence in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.,” Cancers (Basel)., vol. 14, no. 10, May 2022, doi: 10.3390/cancers14102452.
P. Cormie and E. M. Zopf, “Exercise medicine for the management of androgen deprivation therapy-related side effects in prostate cancer.,” Urol. Oncol., vol. 38, no. 2, pp. 62–70, Feb. 2020, doi: 10.1016/j.urolonc.2018.10.008.
S. Loeb, A. Kettermann, L. Ferrucci, P. Landis, E. J. Metter, and H. B. Carter, “PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.,” Eur. Urol., vol. 54, no. 5, pp. 1073–1080, Nov. 2008, doi: 10.1016/j.eururo.2008.06.076.
Q. Chen et al., “A study on the impact of marital status on the survival status of prostate cancer patients based on propensity score matching.,” Sci. Rep., vol. 14, no. 1, p. 6162, Mar. 2024, doi: 10.1038/s41598-024-56145-8.
P. H. Viale, “The American Cancer Society’s Facts & Figures: 2020 Edition.,” Journal of the advanced practitioner in oncology, vol. 11, no. 2. United States, pp. 135–136, Mar. 2020. doi: 10.6004/jadpro.2020.11.2.1.
C. K. (eds) Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, “SEER Cancer Statistics Review, 1975-2017,” Natl. Cancer Institute. Bethesda, MD, 2017.
N. C. Sheets et al., “Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.,” JAMA, vol. 307, no. 15, pp. 1611–1620, Apr. 2012, doi: 10.1001/jama.2012.460.
D. F. Penson et al., “5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study.,” J. Urol., vol. 179, no. 5 Suppl, pp. S40-4, May 2008, doi: 10.1016/j.juro.2008.03.136.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Tomasz Kucharski, Julita Gmitrzuk, Zuzanna Malinka, Katarzyna Wiśniewska, Anna Jachymek, Martyna Opatowska, Joanna Jakubiec, Marta Piotrowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 150
Number of citations: 0
